NASDAQ:ACHN - Achillion Pharmaceuticals Stock Price, Price Target & More

$3.73 +0.08 (+2.19 %)
(As of 04/23/2018 11:30 AM ET)
Previous Close$3.65
Today's Range$3.64 - $3.73
52-Week Range$2.58 - $5.66
Volume118,826 shs
Average Volume1.92 million shs
Market Capitalization$503.32 million
P/E Ratio-6.02
Dividend YieldN/A
Beta0.88

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trial; ACH-5548, a factor D inhibitor; and other factor D inhibitors. It has license agreements with GCA Therapeutics, Ltd and Ora, Inc., as well as a collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize drug candidates for the treatment of chronic hepatitis C virus. The company was founded in 1998 and is headquartered in New Haven, Connecticut.

Receive ACHN News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACHN
CUSIP00448Q20
Phone203-624-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio23.60%
Quick Ratio23.60%

Price-To-Earnings

Trailing P/E Ratio-6.02
Forward P/E Ratio-6.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$15 million
Price / Sales34.29
Cash FlowN/A
Price / CashN/A
Book Value$2.35 per share
Price / Book1.59

Profitability

EPS (Most Recent Fiscal Year)($0.62)
Net Income$-85,230,000.00
Net MarginsN/A
Return on Equity-24.09%
Return on Assets-23.22%

Miscellaneous

Employees88
Outstanding Shares137,900,000

How to Become a New Pot Stock Millionaire

Achillion Pharmaceuticals (NASDAQ:ACHN) Frequently Asked Questions

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals (NASDAQ:ACHN) issued its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.00. During the same period in the previous year, the company earned ($0.03) EPS. View Achillion Pharmaceuticals' Earnings History.

When is Achillion Pharmaceuticals' next earnings date?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Achillion Pharmaceuticals.

What guidance has Achillion Pharmaceuticals issued on next quarter's earnings?

Achillion Pharmaceuticals updated its FY18 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of ($0.58-0.55) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.71).

What price target have analysts set for ACHN?

7 equities research analysts have issued 12-month target prices for Achillion Pharmaceuticals' stock. Their predictions range from $3.50 to $7.00. On average, they expect Achillion Pharmaceuticals' share price to reach $5.00 in the next year. View Analyst Ratings for Achillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:
  • Dr. Milind S. Deshpande, CEO & Director (Age 61)
  • Mr. Joseph Truitt, Pres & COO (Age 53)
  • Ms. Mary Kay Fenton, Exec. VP, CFO & Principal Accounting Officer (Age 54)
  • Glenn Schulman, Exec. Director of Investor Relations
  • Ms. Martha E. Manning, Exec. VP, Gen. Counsel & Corp. Sec. (Age 63)

Has Achillion Pharmaceuticals been receiving favorable news coverage?

News stories about ACHN stock have been trending somewhat negative on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Achillion Pharmaceuticals earned a daily sentiment score of -0.02 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.14 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Achillion Pharmaceuticals?

Shares of ACHN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $3.73.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $503.32 million and generates $15 million in revenue each year. The biopharmaceutical company earns $-85,230,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Achillion Pharmaceuticals employs 88 workers across the globe.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The biopharmaceutical company can be reached via phone at 203-624-7000.


MarketBeat Community Rating for Achillion Pharmaceuticals (ACHN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  376 (Vote Outperform)
Underperform Votes:  276 (Vote Underperform)
Total Votes:  652
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACHN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Achillion Pharmaceuticals (NASDAQ:ACHN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Achillion Pharmaceuticals in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 34.05%. The high price target for ACHN is $7.00 and the low price target for ACHN is $3.50. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.432.432.502.57
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$5.30$6.75
Price Target Upside: 34.05% upside71.23% upside80.58% upside74.87% upside

Achillion Pharmaceuticals (NASDAQ:ACHN) Consensus Price Target History

Price Target History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals (NASDAQ:ACHN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018B. RileyInitiated CoverageNeutral -> Neutral$3.50MediumView Rating Details
12/11/2017Leerink SwannReiterated RatingBuy$5.00MediumView Rating Details
9/17/2017Chardan CapitalReiterated RatingNeutralHighView Rating Details
9/12/2017Ladenburg ThalmannLower Price TargetBuy -> Buy$9.00 -> $6.50HighView Rating Details
9/12/2017Robert W. BairdReiterated RatingNeutral$5.00 -> $4.00HighView Rating Details
8/9/2017Maxim GroupSet Price TargetBuy$5.00 -> $7.00HighView Rating Details
4/26/2017Jefferies GroupReiterated RatingHoldLowView Rating Details
11/3/2016WedbushReiterated RatingOutperform$13.00N/AView Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00N/AView Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Achillion Pharmaceuticals (NASDAQ:ACHN) Earnings History and Estimates Chart

Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals (NASDAQ:ACHN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.74)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.17)($0.16)($0.17)
Q2 20182($0.19)($0.17)($0.18)
Q3 20182($0.21)($0.17)($0.19)
Q4 20182($0.22)($0.18)($0.20)

Achillion Pharmaceuticals (NASDAQ ACHN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2018($0.15)N/AView Earnings Details
2/22/2018Q4 2017($0.1640)($0.1680)ViewListenView Earnings Details
11/1/2017Q3 2017($0.18)($0.14)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.16)($0.16)ViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.18)($0.03)$15.00 millionViewN/AView Earnings Details
11/3/2016Q3($0.16)($0.15)ViewN/AView Earnings Details
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.0920$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.19)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.17)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
8/7/2013Q2 2013($0.16)($0.21)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
2/20/2013Q4 2012($0.19)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.17)($0.16)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.15)($0.13)ViewN/AView Earnings Details
3/8/2012Q4 2011($0.16)($0.18)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.17)($0.15)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.17)($0.19)ViewN/AView Earnings Details
5/4/2011Q1 2011($0.14)($0.17)ViewN/AView Earnings Details
3/2/2011Q4 2010($0.13)($0.11)ViewN/AView Earnings Details
10/27/2010Q3 2010($0.15)($0.15)ViewN/AView Earnings Details
8/13/2010Q2 2010($0.17)($0.17)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.20)($0.16)ViewN/AView Earnings Details
3/12/2010Q4 2009($0.22)($0.25)ViewN/AView Earnings Details
11/6/2009Q3 2009($0.21)($0.23)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.25)($0.23)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.25)($0.25)ViewN/AView Earnings Details
3/25/2009Q4 2008($0.28)($0.33)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.28)($0.31)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.38)($0.43)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.38)($0.38)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.45)($0.44)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Achillion Pharmaceuticals (NASDAQ:ACHN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Achillion Pharmaceuticals (NASDAQ ACHN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 82.10%
Insider Trading History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals (NASDAQ ACHN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/20/2017& Johnson JohnsonMajor ShareholderSell18,367,346$2.75$50,510,201.50View SEC Filing  
12/22/2016Jason S FishermanDirectorBuy10,000$3.96$39,600.0050,000View SEC Filing  
12/5/2016Mary Kay FentonCFOBuy2,500$4.11$10,275.002,500View SEC Filing  
12/2/2016Joel C BarrishInsiderBuy2,500$4.06$10,150.002,500View SEC Filing  
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.0031,431View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.2031,431View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00100,000View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.0040,000View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.0025,000View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.0090,000View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Achillion Pharmaceuticals (NASDAQ ACHN) News Headlines

Source:
DateHeadline
Achillion Pharmaceuticals (ACHN) Downgraded by BidaskClubAchillion Pharmaceuticals (ACHN) Downgraded by BidaskClub
www.americanbankingnews.com - April 18 at 6:54 PM
Achillion Pharmaceuticals (ACHN) Expected to Announce Earnings of -$0.14 Per ShareAchillion Pharmaceuticals (ACHN) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 18 at 5:18 PM
Achillion Pharmaceuticals (ACHN) Receives Consensus Recommendation of "Hold" from BrokeragesAchillion Pharmaceuticals (ACHN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 9:15 AM
Achillion Pharmaceuticals (ACHN) Stock Rating Lowered by BidaskClubAchillion Pharmaceuticals (ACHN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 16 at 12:02 PM
Investor Expectations to Drive Momentum within Credicorp, Essent Group, Achillion Pharmaceuticals, Banco Santander, S.A, Check Point Software Technologies, and Fomento Economico Mexicano S.A.B. de C.V — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Credicorp, Essent Group, Achillion Pharmaceuticals, Banco Santander, S.A, Check Point Software Technologies, and Fomento Economico Mexicano S.A.B. de C.V — Discovering Underlying Factors of Influence
finance.yahoo.com - April 9 at 8:41 AM
Achillion Pharmaceuticals (ACHN) Neutral Rating Reiterated at Robert W. BairdAchillion Pharmaceuticals' (ACHN) Neutral Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - April 8 at 11:23 PM
Achillion Pharmaceuticals (ACHN) Cut to "Hold" at BidaskClubAchillion Pharmaceuticals (ACHN) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 3 at 8:57 AM
Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.14 Per ShareAchillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.14 Per Share
www.americanbankingnews.com - April 1 at 5:10 PM
Achillion Pharmaceuticals (ACHN) Downgraded by Zacks Investment ResearchAchillion Pharmaceuticals (ACHN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 1 at 12:40 AM
Achillion Pharmaceuticals (ACHN) Lowered to "Hold" at Zacks Investment ResearchAchillion Pharmaceuticals (ACHN) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 31 at 11:46 AM
BidaskClub Upgrades Achillion Pharmaceuticals (ACHN) to "Sell"BidaskClub Upgrades Achillion Pharmaceuticals (ACHN) to "Sell"
www.americanbankingnews.com - March 25 at 3:47 PM
BidaskClub Upgrades Achillion Pharmaceuticals (ACHN) to "Buy"BidaskClub Upgrades Achillion Pharmaceuticals (ACHN) to "Buy"
www.americanbankingnews.com - March 24 at 1:36 PM
Achillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of "Hold" from AnalystsAchillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 9:18 AM
Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock?Are Options Traders Betting on a Big Move in Achillion Pharmaceuticals (ACHN) Stock?
www.zacks.com - March 20 at 8:46 AM
Achillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - SlideshowAchillion Pharmaceuticals (ACHN) Presents At Barclays Global Healthcare Conference 2018 - Slideshow
seekingalpha.com - March 16 at 6:14 PM
-$0.14 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter-$0.14 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter
www.americanbankingnews.com - March 15 at 1:51 PM
Achillion Pharmaceuticals, Inc. (ACHN) Short Interest UpdateAchillion Pharmaceuticals, Inc. (ACHN) Short Interest Update
www.americanbankingnews.com - March 11 at 1:58 AM
Achillion to Present at the Barclays Global Healthcare Conference - NasdaqAchillion to Present at the Barclays Global Healthcare Conference - Nasdaq
www.nasdaq.com - March 8 at 8:40 AM
Emory University Has $1.49 Million Holdings in Achillion Pharmaceuticals, Inc. (ACHN)Emory University Has $1.49 Million Holdings in Achillion Pharmaceuticals, Inc. (ACHN)
www.americanbankingnews.com - March 4 at 3:02 PM
Spark Investment Management LLC Buys 422,800 Shares of Achillion Pharmaceuticals, Inc. (ACHN)Spark Investment Management LLC Buys 422,800 Shares of Achillion Pharmaceuticals, Inc. (ACHN)
www.americanbankingnews.com - March 2 at 12:29 PM
Achillion Pharmaceuticals (ACHN) Stock Rating Upgraded by Zacks Investment ResearchAchillion Pharmaceuticals (ACHN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 27 at 12:39 PM
Achillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in SessionAchillion Pharmaceuticals (ACHN) Soars: Stock Adds 15.4% in Session
www.zacks.com - February 27 at 8:37 AM
Why Achillion Pharmaceuticals, Inc. Stock Spiked TodayWhy Achillion Pharmaceuticals, Inc. Stock Spiked Today
finance.yahoo.com - February 27 at 8:37 AM
Today’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and NovavaxToday’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Novavax
finance.yahoo.com - February 27 at 8:37 AM
Achillion Pharmaceuticals, Inc. (ACHN) Receives Average Recommendation of "Hold" from BrokeragesAchillion Pharmaceuticals, Inc. (ACHN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - February 27 at 7:36 AM
Mid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares SurgeMid-Afternoon Market Update: Telaria Falls Following Q4 Results; Achillion Pharmaceuticals Shares Surge
feeds.benzinga.com - February 26 at 4:17 PM
Achillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.16 Per ShareAchillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - February 26 at 1:16 PM
Achillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save CostAchillion (ACHN) Q4 Loss Widens, Plans Job Cuts to Save Cost
www.zacks.com - February 23 at 8:39 AM
Form 8-K ACHILLION PHARMACEUTICAL For: Feb 22Form 8-K ACHILLION PHARMACEUTICAL For: Feb 22
www.streetinsider.com - February 22 at 5:27 PM
Was Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn?Was Achillion Pharmaceuticals Inc’s (NASDAQ:ACHN) Earnings Decline A Part Of Broader Industry Downturn?
finance.yahoo.com - February 22 at 5:27 PM
Achillion Pharmaceuticals (ACHN) Announces Quarterly  Earnings Results, Misses Estimates By $0.01 EPSAchillion Pharmaceuticals (ACHN) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - February 22 at 10:50 AM
Achillion Pharmaceuticals (ACHN) Updates FY18 Earnings GuidanceAchillion Pharmaceuticals (ACHN) Updates FY18 Earnings Guidance
www.americanbankingnews.com - February 22 at 10:09 AM
Achillion Pharmaceuticals (ACHN) Upgraded by BidaskClub to "Hold"Achillion Pharmaceuticals (ACHN) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - February 19 at 3:38 PM
Achillion to Present at the Leerink Partners 7th Annual Global Healthcare ConferenceAchillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 17 at 8:25 AM
Achillion Pharmaceuticals, Inc. Expected to Earn FY2017 Earnings of ($0.59) Per Share (ACHN)Achillion Pharmaceuticals, Inc. Expected to Earn FY2017 Earnings of ($0.59) Per Share (ACHN)
www.americanbankingnews.com - February 12 at 1:08 AM
Achillion Pharmaceuticals (ACHN) Research Coverage Started at B. RileyAchillion Pharmaceuticals (ACHN) Research Coverage Started at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Achillion Pharmaceuticals, Inc. (ACHN) Receives Average Rating of "Hold" from AnalystsAchillion Pharmaceuticals, Inc. (ACHN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 2 at 12:34 PM
Achillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.15 Per ShareAchillion Pharmaceuticals, Inc. (ACHN) Expected to Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - January 23 at 11:06 PM
Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value - Seeking AlphaAchillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value - Seeking Alpha
seekingalpha.com - January 10 at 6:36 AM
Achillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Hold" by BrokeragesAchillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 8 at 8:38 AM
Technical Perspectives on Cytokinetics, Geron, Achillion Pharma, and Calithera Biosciences - PR Newswire (press release)Technical Perspectives on Cytokinetics, Geron, Achillion Pharma, and Calithera Biosciences - PR Newswire (press release)
www.prnewswire.com - December 29 at 9:24 AM
Alexion's (ALXN) Soliris Label Expansion Approved in JapanAlexion's (ALXN) Soliris Label Expansion Approved in Japan
finance.yahoo.com - December 27 at 9:54 AM
BioMarins (BMRN) Pegvaliase Review Period Extended by FDABioMarin's (BMRN) Pegvaliase Review Period Extended by FDA
finance.yahoo.com - December 26 at 11:29 PM
Achillion Pharmaceuticals (ACHN) Raised to "Sell" at BidaskClubAchillion Pharmaceuticals (ACHN) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - December 23 at 5:04 PM
CORRECTION - Achillion Pharmaceuticals, Inc.CORRECTION - Achillion Pharmaceuticals, Inc.
finance.yahoo.com - December 20 at 3:18 PM
Achillion Pharma (ACHN) Commences Phase I First-In Study of ACH-5228 - StreetInsider.comAchillion Pharma (ACHN) Commences Phase I First-In Study of ACH-5228 - StreetInsider.com
www.streetinsider.com - December 20 at 6:15 AM
Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor DAchillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
finance.yahoo.com - December 20 at 6:15 AM
Achillions Renal Disease Candidate Gets Orphan Drug StatusAchillion's Renal Disease Candidate Gets Orphan Drug Status
www.nasdaq.com - December 19 at 3:18 PM
Achillion Pharma (ACHN) Granted FDA Orphan Drug Designation for ACH-4471 & Initiation of Phase 1 Extended ... - StreetInsider.comAchillion Pharma (ACHN) Granted FDA Orphan Drug Designation for ACH-4471 & Initiation of Phase 1 Extended ... - StreetInsider.com
www.streetinsider.com - December 19 at 6:30 AM
Twitter Up 5% on Better RatingTwitter Up 5% on Better Rating
finance.yahoo.com - December 18 at 3:18 PM

SEC Filings

Achillion Pharmaceuticals (NASDAQ:ACHN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Achillion Pharmaceuticals (NASDAQ:ACHN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Achillion Pharmaceuticals (NASDAQ ACHN) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.